A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.

开始日期2025-01-03

申办/合作机构

Loxo Oncology, Inc.

[+1]

NCT06104683

/ Withdrawn临床2期

A Phase 2, Randomized Study of Pirtobrutinib Versus Placebo in Patients With Relapsing Multiple Sclerosis

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

开始日期2024-05-01

申办/合作机构

Loxo Oncology, Inc.

[+1]

NCT06043674

/ Recruiting临床2期IIT

A Phase 2 Study of Glofitamab as Monotherapy or in Combination With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT).
The names of the study drugs involved in this research study are:
* Glofitamab (a T-cell bispecific humanized monoclonal antibody)
* Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody)
* Polatuzumab vedotin (an antibody-drug conjugate)
* Pirtobrutinib (a selective inhibitor of BTK)
* Atezolizumab (a humanized immunoglobulin monoclonal antibody)
* Tocilizumab (a recombinant, humanized, anti-human monoclonal antibody)

开始日期2024-01-22

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+3]

100 项与 Loxo Oncology, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Loxo Oncology, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Loxo Oncology, Inc. 相关的文献（医药）

2023-03-01·Chem

First trans-eunicellane terpene synthase in bacteria

Article

作者: Kojasoy, Volga ; Li, Zining ; Ning, Wenbo ; Ortega, Teresa ; Tantillo, Dean J ; Wei, Xiuting ; Loesgen, Sandra ; Adpressa, Donovon A ; Liu, Jamin ; Rudolf, Jeffrey D ; Xu, Baofu

Terpenoids are the largest family of natural products, but prokaryotes are vastly underrepresented in this chemical space. However, genomics supports vast untapped biosynthetic potential for terpenoids in bacteria. We discovered the first trans-eunicellane terpene synthase (TS), AlbS from Streptomyces albireticuli NRRL B-1670, in nature. Mutagenesis, deuterium labeling studies, and quantum chemical calculations provided extensive support for its cyclization mechanism. In addition, parallel stereospecific labeling studies with Bnd4, a cis-eunicellane TS, revealed a key mechanistic distinction between these two enzymes. AlbS highlights bacteria as a valuable source of novel terpenoids, expands our understanding of the eunicellane family of natural products and the enzymes that biosynthesize them, and provides a model system to address fundamental questions about the chemistry of 6,10-bicyclic ring systems.

2022-06-01·Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer1区 · 医学

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

1区 · 医学

Article

作者: Zhu, Viola W ; Olek, Elizabeth A ; Kherani, Jennifer F ; Park, Keunchil ; McCoach, Caroline E ; Soldatenkova, Victoria ; Muehlenbein, Catherine E ; Goto, Koichi ; Lacouture, Mario ; Rolfo, Christian ; Drilon, Alexander ; Potter, Laura A ; Tan, Daniel S W ; Besse, Benjamin ; Farajian, Stephanie

INTRODUCTION:

Immune checkpoint inhibitor (ICI) therapy has been found to increase the risk/severity of immune-mediated adverse events with subsequent kinase inhibitor treatment in oncogenically driven cancers. We explored the risk for hypersensitivity with selpercatinib, a first-in-class highly selective and potent, central nervous system-active RET inhibitor, in prior ICI-treated patients with RET fusion-positive NSCLC compared with their ICI-naive counterparts.

METHODS:

Data from patients enrolled by December 16, 2019, in the ongoing phase 1/2 LIBRETTO-001 (NCT03157128) trial were analyzed for hypersensitivity reactions reported using preferred terms of hypersensitivity/drug hypersensitivity and defined as a constellation of symptoms/findings characterized by maculopapular rash, often preceded by fever with arthralgias/myalgias, followed by greater than or equal to 1 of the following signs/symptoms: thrombocytopenia, increased aspartate aminotransferase or alanine aminotransferase, hypotension, tachycardia, or increased creatinine.

RESULTS:

Of 329 patients, 22 (7%) who experienced a grade 1 to 3 hypersensitivity reaction that met the defined constellation of events were attributed to selpercatinib by investigators, and more often in prior ICI-treated (n = 17, 77%) than ICI-naive (n = 5, 23%) patients. There were 19 patients with selpercatinib-related hypersensitivity who resumed selpercatinib post-hypersensitivity with dose modification/supportive care. Furthermore, 17 patients, of whom 14 received prior ICI therapy, were still on treatment at twice daily doses of 40 mg (n = 5), 80 mg (n = 4), 120 mg (n = 4), and 160 mg (n = 4).

CONCLUSIONS:

Rates of selpercatinib-related hypersensitivity were low overall and, as with other kinase inhibitors, occurred predominantly in prior ICI-treated patients. Hypersensitivity to selpercatinib can be managed with supportive care measures regardless of prior ICI status and is reversible.

2021-11-01·JCO precision oncology4区 · 医学

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer

4区 · 医学

Article

作者: Takeda, Masayuki ; Sakai, Kazuko ; Ito, Akihiko ; Otani, Tomoyuki ; Rothenberg, S. Michael ; Kherani, Jennifer ; Watanabe, Satomi ; Nakagawa, Kazuhiko ; French, Pearl P. ; Yoshida, Takeshi ; Olek, Elizabeth ; Nishio, Kazuto

First Page

314

项与 Loxo Oncology, Inc. 相关的新闻（医药）

2026-06-01

·抗体圈

ASCO重磅突破！礼来Retevmo实现肺癌早晚期全覆盖，83%风险大幅下降

2026年5月31日，2026年美国临床肿瘤学会（ASCO）年会全体大会发布一项全球首创的肿瘤精准治疗重磅成果。礼来制药旗下高选择性RET靶向抑制剂塞尔帕替尼（Retevmo/selpercatinib），在针对早期RET融合阳性非小细胞肺癌（NSCLC）的关键性III期Libretto-432辅助治疗研究中，斩获突破性阳性终点数据，成功将患者疾病复发或死亡风险大幅降低83%，疗效表现堪称颠覆性。据悉，这是全球首个证实选择性RET激酶抑制剂可用于早期肺癌辅助治疗且取得III期阳性结果的临床研究。该成果正式补齐了RET融合阳性肺癌全病程治疗的最后一块拼图，标志着该罕见靶点肺癌正式迈入标准化、精准化的全程管控新时代，充分彰显了生物标志物精准诊疗的核心临床价值。核心数据：83% 风险降低，疗效堪称 "戏剧性" 本次重磅公布的Libretto-432 III期临床研究，共入组151例经根治性手术或放疗（可联合或不联合化疗）的早期RET融合阳性非小细胞肺癌患者，受试者随机分组接受最长3年的Retevmo靶向治疗或安慰剂对照治疗，核心评估药物辅助治疗的有效性与安全性。经中位随访评估，该研究顺利达成主要无事件生存期（EFS）终点，核心疗效数据十分亮眼： 2-3A期核心人群：Retevmo治疗组24个月无事件生存率（EFS）高达92%，安慰剂组仅为61%，疾病复发、进展或死亡风险显著降低83%（HR=0.17），疗效差异极具统计学意义与临床价值。 1B-3A期全体人群：整体随访数据同样优势显著，Retevmo治疗组24个月EFS率达94%，远超安慰剂组的70%，各分期患者均可明确获益。总生存期（OS）：目前OS数据尚未成熟，但已呈现出明显偏向Retevmo治疗组的积极趋势，长期生存获益潜力可期。礼来肿瘤事业部总裁兼企业业务发展负责人Jacob Van Naarden在受访时，将本次研究的疗效成果评价为“戏剧性突破”。他表示，RET融合突变肿瘤对RET靶向抑制剂具备极高的药物敏感性，而本次早期辅助治疗的优异数据，再次充分验证了这一核心药理特性，也印证了靶向治疗前移的巨大临床价值。填补空白：早期 RET 肺癌首次迎来靶向治疗 RET融合属于非小细胞肺癌中相对罕见的驱动基因突变，整体突变率仅为1%-2%。虽发病率偏低，但依托肺癌庞大的患者基数，全球每年新增RET融合阳性肺癌患者数量不容小觑，临床诊疗需求长期存在。在本次研究落地前，EGFR、ALK等常见肺癌靶点的靶向药物早已实现早期辅助治疗的临床落地，成为改善早癌患者预后的核心方案。但长期以来，RET融合阳性早期肺癌患者始终无专属靶向治疗手段，术后仅能依靠传统化疗巩固疗效，疾病复发风险居高不下，临床存在巨大的未满足治疗需求。 “与EGFR、ALK靶点不同，此前早期RET融合肺癌患者一直缺乏有效的靶向治疗方案。”Van Naarden坦言，“Libretto-432研究的成功，正式让RET跻身早期肺癌常规检测靶点行列，与EGFR、ALK三足鼎立，补齐了早期精准诊疗的关键短板。”行业影响：推动 RET 检测全面普及 Libretto-432研究的突破性结果，不仅为早期RET融合阳性肺癌患者提供了高效全新的巩固治疗方案，更深刻重塑了肺癌精准诊疗的整体格局，推动罕见靶点诊疗走向规范化、常态化。礼来官方表示，该研究数据强有力证实了肺癌早期开展RET基因检测的必要性与临床价值。当前国内临床中，RET靶点的常规检测普及度远低于EGFR、ALK，而Retevmo辅助治疗适应症的即将落地，将彻底改变这一现状，推动RET检测纳入早期肺癌常规筛查体系。 “这是清晰的生物学诊疗逻辑。”Van Naarden解释道，“对于已普及EGFR、ALK早期靶向诊疗的临床场景而言，RET靶点如今正式补齐短板，成为早期肺癌精准治疗不可或缺的重要组成部分。”产品历程：从晚期到早期，完成全病程覆盖作为全球首款高选择性RET抑制剂，Retevmo于2020年获美国FDA获批上市，最初获批用于晚期RET融合阳性肺癌、甲状腺癌的治疗。2022年，该药物再度拓展适应症，获批用于所有RET融合驱动的局部晚期、转移性实体瘤，成为不限癌种的广谱精准抗肿瘤药物，靶点价值持续释放。此次早期肺癌辅助治疗适应症的突破，让Retevmo成功实现从晚期姑息治疗到早期根治辅助的**全病程治疗覆盖**，彻底夯实了其在全球RET靶向治疗领域的标杆地位，成为该靶点唯一贯穿肺癌全程诊疗的核心药物。公开资料显示，Retevmo是礼来2019年斥资80亿美元收购Loxo Oncology斩获的核心管线资产。2024年，礼来做出精准战略布局，主动放弃下一代RET抑制剂的研发，集中全部资源深耕Retevmo的适应症拓展与临床应用。本次Libretto-432研究的大获成功，充分印证了礼来此次战略决策的前瞻性与正确性。从商业化表现来看，Retevmo市场增长势头稳健。财报数据显示，其2024年全球销售额达3.64亿美元，2025年销售额攀升至4.56亿美元，同比实现稳步增长。随着早期肺癌百亿级新市场的打开，该药物的商业化潜力将进一步全面释放，有望成为礼来肿瘤管线新的增长极。据Van Naarden透露，礼来已启动适应症申报筹备工作，计划在未来数月内，向全球各大药监机构递交Retevmo早期肺癌辅助治疗适应症的上市申请，推动这一创新方案快速落地临床。 “从药物研发全局来看，这基本完成了Retevmo核心研发管线的最终布局。”Van Naarden总结道，“这是该药物研发历程的收官篇章，也是极具里程碑意义的精彩篇章。” 参考来源：https://www.fiercepharma.com/pharma/asco-lilly-ties-retevmo-dramatic-outcomes-early-stage-lung-cancer-rare-ret-biomarker 识别微信二维码，添加抗体圈小编，符合条件者即可加入抗体微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

2026-05-31

·FiercePharma

ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker

Lilly's upcoming label expansion proposal for 2020-approved Retevmo is "in many ways, the final chapter of the development program" for the drug, oncology head Jacob Var Naarden said in an interview. UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM ESTSix years after hitting the market as the first targeted treatment for patients with a rare genetic tumor mutation, Eli Lilly’s Retevmo (selpercatinib) is solidifying its legacy with a new study that has shown “dramatic” outcomes and showcases the importance of RET fusion biomarker testing.With several broad indications to its name, Retevmo has been targeting tumors with alterations in the rearranged during transfection (RET) gene for years now. However, the early-stage RET-fusion positive non-small cell lung cancer (NSCLC) patient population has yet to see major benefits from this push—until Lilly’s phase 3 Libretto-432. Presented during the plenary session at the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Libretto-432 saw Retevmo able to reduce the risk of disease reoccurrence or death by a whopping 83% over placebo. The study was the first trial of its kind of weigh a selective RET kinase inhibitor as an adjuvant therapy in the patient population, Lilly pointed out in a May 31 press release, and took place among 151 patients who received treatment or placebo for up to three years after radiotherapy or surgery, with or without chemotherapy. At 24 months in the primary analysis population of those with stage 2-3A disease, the event-free survival rate for Retevmo-treated patients was 92% compared to 61% in the placebo group. For the wider overall study population of patients with stage 1B-3A disease, event-free survival rates came out to 94% in the treatment arm and 70% in the placebo group, Lilly reported. Overall survival results, meanwhile, “trended in favor” of Retevmo but were immature at the time of analysis, according to the company. Although RET fusions are more rare than other more commonly known cancer mutations such as EGFR and ALK, the results serve to establish RET fusions as a key biomarker to test for across all disease stages, the company said. RET fusions are seen in 1% to 2% of patients with NSCLC, study authors point out. “Unlike EGFR and ALK, until now these patients have not had a way of addressing their disease when it occurs in the early-stage setting,” Lilly’s president of oncology and head of corporate business development, Jacob Van Naarden, explained in a recent interview with Fierce, noting that Libretto-432 “credentializes RET and selpercatinib in that same context.” Two years after Retevmo’s market debut as a treatment for more advanced lung and thyroid cancers with a RET mutation, the drug snatched a much wider label to cover all locally advanced or metastatic solid tumors driven by the biomarker. Since then, it has become a dominant standard-of-care for the specific patient group, whose genomic alteration makes them “exquisitely sensitive” to the treatment, Van Naarden said. To Lilly and Van Naarden, the “dramatic efficacy” seen across Retevmo’s studies reasserts the need for RET genomic tests during the early treatment process. While this testing is not exactly simple, the executive proposes that the extent of testing done for EGFR and ALK biomarkers, for example, should be commonplace for RET as well. “There’s an underlying through line of biology here,” Van Naarden explained. “For lung cancer physicians and patients who have adopted EGFR and ALK directive therapies in early stage diagnosis,” RET is now also “firmly in the mix,” he emphasized. Lilly plans to use the trial results as the basis for a proposed label expansion with global drug regulators “over the next couple months,” Van Naarden confirmed. “This is in many ways the final chapter of the development program for this medicine,” the exec added, “but an exciting one, for sure.” Given the rare nature of the biomarker, Retevmo isn’t much of a sales driver in Lilly’s oncology portfolio, generating sales of $364 million in 2024 and $456 million last year. The company essentially put all its RET chips in the drug after walking away from a next-generation RET inhibitor in 2024, which was meant to overcome acquired resistance to Retevmo. Both Retevmo and its scrapped successor came to Lilly from its $8 billion takeover of Loxo Oncology in 2019.

并购ASCO会议临床3期临床结果

2026-05-10

·萤火虫Bio

23亿美元！礼来三周内第三笔肿瘤收购，押注罕见血癌下一代疗法

近日，礼来公司宣布以最高23亿美元的现金对价收购生物制药公司Ajax Therapeutics，这是礼来近一个月内落地的第三笔肿瘤领域收购。根据协议，Ajax股东将获得包含预付款及未来临床、监管里程碑达成后的或有付款。密集的交易节奏让业界再次将目光投向这家制药巨头在罕见血液肿瘤领域的野心，而Ajax的核心资产——一款针对骨髓增殖性肿瘤（MPN）的下一代JAK2抑制剂，有望填补当前疗法耐药后的治疗空白。 Ajax Therapeutics成立于2019年，总部位于纽约，由纪念斯隆·凯特琳癌症中心的科学家联合创立，是一家专注于MPN领域的临床阶段生物制药公司。公司借助Schrödinger的计算化学平台进行药物发现，累计融资超过1.35亿美元，礼来此前已是其创始战略投资者，并参与了2024年的C轮融资。目前Ajax尚无产品上市，但拥有一条备受瞩目的在研管线，具体情况如下表所示：产品名称靶点适应症临床阶段备注 AJ1-11095 II型JAK2 骨髓纤维化 I期（AJX-101）每日一次口服获FDA孤儿药资格 — — 真性红细胞增多症等临床前/规划中礼来计划拓展适应症范围 AJ1-11095是此次收购的核心标的。这是一款首创、每日一次口服的高选择性II型JAK2抑制剂，其作用机制与目前已上市的JAK2抑制剂截然不同。现有药物如ruxolitinib、fedratinib均靶向JAK2蛋白的I型构象，虽然能缩小患者脾脏、改善症状，但疗效不持久、易产生耐药，且对骨髓纤维化背后的致病机制影响有限。AJ1-11095通过结合II型构象，旨在提供更深层、更持久的疾病控制，尤其为对I型JAK2抑制剂耐药或应答不佳的骨髓纤维化患者带来全新选择。目前该药正处于I期AJX-101试验中，概念验证数据预计于2026年下半年公布。礼来此次收购的战略意图十分清晰。首先，通过获得AJ1-11095，礼来将直接切入MPN这一罕见病赛道，填补耐药治疗领域的空白，并有望将该药从二线治疗推向一线。礼来肿瘤业务总裁Jacob Van Naarden明确表示，期待AJ1-11095在疗效强度、持久性及耐受性上超越现有方案，从而改变骨髓纤维化的治疗格局。其次，尽管礼来已在免疫领域拥有JAK抑制剂Olumiant，但通过Ajax，公司得以将JAK平台延伸至血液肿瘤，完善自身在肿瘤领域的管线布局。最后，礼来近年来凭借减肥药替尔泊肽获得丰厚现金流，密集收购肿瘤资产的背后，也是公司分散业务风险、巩固肿瘤治疗护城河的战略选择。值得注意的是，这笔收购并非孤立事件。4月7日，礼来以80亿美元收购Loxo Oncology；4月14日，收购CrossBridge Bio；4月中旬还以70亿美元收购Kelonia Therapeutics——加上此次23亿美元的Ajax，礼来在一个月内连续出手，覆盖精准肿瘤药物、ADC、体内CAR-T以及罕见血液肿瘤等多个前沿方向。如此密集的“扫货式”收购，展现了礼来对肿瘤领域的高度重视和强大的资本执行力，也反映出大型制药企业通过外部创新弥补内部研发短板的行业趋势。展望未来，AJ1-11095具备显著的商业潜力。若I期数据积极并顺利推进至注册临床，它有望成为首个获批的II型JAK2抑制剂，在传统I型JAK2抑制剂失败的场景下建立标准疗法。礼来在血液肿瘤临床开发和商业化方面的丰富经验，将加速该药物的后续研发。此外，Ajax的研发平台还可拓展至更多MPN亚型甚至其他JAK驱动疾病，为礼来带来长远的管线价值。随着2026年下半年概念验证数据的读出，这项23亿美元押注的成色将逐步揭晓。专注药用高分子材料，助力药械研发高质量前行。如果您正在开展PEG 化药物、水凝胶器械、PLA/PLGA 微球等项目开发，有样品测试、原料供应需求，欢迎随时与我们交流对接。作为专业的药用高分子材料研发与制造方，我们可提供克级实验室样品、公斤级中试、吨级工业化生产的全链条供应，支持nGMP 及 GMP级别药用 PEG、PLA、PLGA 原料定制，并提供完整、规范的质量研究报告。我们以高标准原料与专业服务，为您的药械研发与申报全程护航，助力创新成果落地，让更安全、更优质的药械福泽广大患者。分类产品分子量 mPEG 原料 mPEG-OH 5K,10K,20K,30k,40K 多臂PEG 原料 4arm-PEG-OH 10K,20K,40K 8arm-PEG(TP)-OH 10K,15K;20K,40K 8arm-PEG(HG)-OH 10K,15K;20K,40K 两臂PEG U-mPEG2-NHS 40K Y-PEG-NHS 40K mPEG2-MAL 40K 单官能团 mPEG-pALD 5K,10K,20K mPEG-bALD 5K,10K,20K mPEG-SC 5K,10K,20K mPEG-SCM 5K,10K,20K mPEG-SPA 5K,10K,20K mPEG-SBA 5K,10K,20K mPEG-SVA 5K,10K,20K mPEG-SHA 5K,10K,20K mPEG-SG 5K,10K,20K mPEG-SS 5K,10K,20K mPEG-MAL 5K,10K,20K mPEG-ppMAL 5K,10K,20K mPEG-NH2 5K,10K,20K mPEG-AA 5K,10K,20K 双官能团 OHC-PEG-CHO 5K,10K,20K HOOC-PEG-COOH 5K,10K,20K HS-PEG-SH 5K,10K,20K H2N-PEG-NH2 5K,10K,20K SC-PEG-SC 5K,10K,20K SCM-PEG-SCM 5K,10K,20K SS-PEG-SS 5K,10K,20K MAL-PEG-CHO 5K,10K,20K MAL-PEG-NHS 5K,10K,20K HOOC-PEG-NCO 5K,10K,20K AA-PEG-EO 5K,10K,20K AA-PEG-SC 5K,10K,20K OHC-PEG-EO 5K,10K,20K H2N-PEG-SH 5K,10K,20K COOH-PEG-SH 5K,10K,20K AA-PEG-COOH 5K,10K,20K OHC-PEG-SC 5K,10K,20K HO-PEG-SH 5K,10K,20K MAL-PEG-PA 5K,10K,20K NH2-PEG-COOH 5K,10K,20K MA-PEG-EO 5K,10K,20K MA-PEG-NCO 5K,10K,20K 四臂PEG 4arm-PEG-SG 10K,20K 4arm-PEG-SS 10K,20K 4arm-PEG-SH 10K,20K 4arm-PEG-NH2 10K,20K 4arm-PEG-pALD 10K,20K 4arm-PEG-bALD 10K,20K 4arm-PEG-MAL 10K,20K 4arm-PEG-SC 10K,20K 4arm-PEG-SCM 10K,20K 4arm-PEG-SPA 10K,20K 4arm-PEG-SBA 10K,20K 4arm-PEG-SVA 10K,20K 4arm-PEG-SHA 10K,20K 4arm-PEG-SSE 10K,20K 4arm-PEG-SCM 10K,20K 4arm-PEG-CHA-NCO 10K,20K 4arm-PEG-HA-MAL 10K,20K 4arm-（3NH2+1AA）-PEG 10K,20K 4arm-PEG-SSA 10K,20K 八臂PEG 8arm-PEG(TP)-SG 10k,15k;20k;40k 8arm-PEG(TP)-SS 10k,15k;20k;40k 8-arm-PEG(TP)-SH 10k,15k;20k;40k 8arm-PEG（TP)-NH2 10k,15k;20k;40k 8arm-PEG(TP)-pALD 10k,15k;20k;40k 8arm-PEG(TP)-MAL 10k,15k;20k;40k 8arm-PEG(HG)-SG 10k,15k;20k;40k 8arm-PEG(HG)-SS 10k,15k;20k;40k 8arm-PEG(HG)-SH 10k,15k;20k;40k 8arm-PEG(HG)-MAL 10k,15k;20k;40k 8arm-PEG(TP)-SC 10k,15k;20k;40k 8arm-PEG(TP)-GA 10k,15k;20k;40k 8arm-PEG(TP)-GAA 10k,15k;20k;40k 8arm-PEG(TP)-SAA 10k,15k;20k;40k 8arm-PEG(TP)-SA 10k,15k;20k;40k 8arm-PEG(TP)-CM 10k,15k;20k;40k 8arm-PEG(TP)-SCM 10k,15k;20k;40k 8arm-PEG(HG)-SGA 10k,15k;20k;40k 8arm-PEG(HG)-SCM 10k,15k;20k;40k 8arm-PEG(HG)-SC 10k,15k;20k;40k 8arm-PEG(HG)-pALD 10k,15k;20k;40k 8arm-PEG(HG)-GA 10k,15k;20k;40k 8arm-PEG(HG)-GAA 10k,15k;20k;40k 8arm-PEG(HG)-SAA 10k,15k;20k;40k 8arm-PEG(HG)-SA 10k,15k;20k;40k 8arm-PEG(HG)-CM 10k,15k;20k;40k 8arm-PEG(SUC)-MAL 10k,15k;20k;40k 8arm-PEG（HY）-SG 10k,15k;20k;40k Linkers NH2-PEGn-PA(n=2-24) AZIDE-PEGn-NH2(n=2-24) AZIDE-PEGn-PA(n=2-24) M-PEGn-PA(n=2-24) M-PEGn-NH2(n=2-24) MAL-PEGn-PA(n=2-24) MAL-PEGn-SPA(n=2-24) DBCO-PEGn-PA(n=2-24) MAL-PEGn-VC-PAB(n=2-24) MAL-PEGn-VA-PAB(n=2-24) DBCO-PEGn-VC-PAB(n=2-24) DBCO-PEGn-VA-PAB(n=2-24) LNPs M-DMG-2000 ALC-0159 ALC-0315 SM-102 DOTAP PLGA 产品型号特性黏度(dL/g) PLGA5050 PLGA5050-20H 0.16-0.24 PLGA5050-30H 0.25-0.35 PLGA5050-40H 0.36-0.44 PLGA5050-20S 0.16-0.24 PLGA5050-30S 0.25-0.35 PLGA5050-40S 0.36-0.44 PLGA6535 PLGA6535-20H 0.16-0.24 PLGA6535-30H 0.25-0.35 PLGA6535-40H 0.36-0.44 PLGA6535-20S 0.16-0.24 PLGA6535-30S 0.25-0.35 PLGA6535-40S 0.36-0.44 PLGA7525 PLGA7525-20H 0.16-0.24 PLGA7525-30H 0.25-0.35 PLGA7525-40H 0.36-0.44 PLGA7525-20S 0.16-0.24 PLGA7525-30S 0.25-0.35 PLGA7525-40S 0.36-0.44 PLGA8515 PLGA8515-20H 0.16-0.24 PLGA8515-30H 0.25-0.35 PLGA8515-40H 0.36-0.44 PLGA8515-20S 0.16-0.24 PLGA8515-30S 0.25-0.35 PLGA8515-40S 0.36-0.44 免责条款：本文内容仅代表作者观点，供行业交流参考，不构成任何投资或应用建议，如有侵权，请联系小编，多谢❀❀❀

100 项与 Loxo Oncology, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Loxo Oncology, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2026年06月12日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

塞普替尼 ( RET )	RET融合阳性甲状腺癌更多	批准上市
匹妥布替尼 ( BTK C481S )	套细胞淋巴瘤更多	临床3期
Selective BRM(Foghorn Therapeutics) ( SMARCA2 x SMARCA4 )	非小细胞肺癌更多	临床前
LOX-18228 ( RET )	肿瘤更多	临床前
F-001 ( FGFR1 )	肿瘤更多	无进展